Mature wines are better: CDC as the leading method to define highly sensitized patients

Current Opinion in Organ Transplantation

Volumn 15, Issue 6, 2010, Pages 716-719

  Doxiadis, Ilias I N ^a   Roelen, Dave ^a   Claas, Frans H J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

DSA; graft loss; highly sensitized patients; HLA antibodies; rejection; transplantation

Indexed keywords

ANTIBODY; DONOR SPECIFIC ANTIBODY; EPITOPE; HLA ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; PANEL REACTIVE ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SCREENING; ANTIBODY TITER; BLOOD GROUP TYPING; COMPLEMENT DEPENDENT CYTOTOXICITY; DIAGNOSTIC ACCURACY; EPSTEIN BARR VIRUS; FLOW CYTOMETRY; HLA MATCHING; HUMAN; IMMUNOASSAY; REVIEW; SENSITIVITY AND SPECIFICITY; SENSITIZATION; SOLID PHASE ASSAY; TREATMENT CONTRAINDICATION;

COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY TESTS, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIBODIES; KIDNEY TRANSPLANTATION;

EID: 78649661292     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283402beb     Document Type: Review

References (22)

1. Terasaki PI, Mcclelland JD. Microdroplet assay of human serum cytotoxins. Nature 1964; 204:998-1000.
2. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejec-tion of kidney allografts, associated with preexisting humoral antibodies against donor cells. Lancet 1966; 2:662-665.
3. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735-739.
4. Tait BD. Solid phase assays for HLA antibody detection in clinical transplantation. Curr Opin Immunol 2009; 21:573-577.
5. Vaidya S. Clinical importance of antihuman leukocyte antigen-specific antibody concentration in performing calculated panel reactive antibody and virtual crossmatches. Transplantation 2008; 85:1046-1050.
6. Amos DB. Cytotoxicity testing. In Manual of tissue typing techniques. NIH publication No.8-545:42, editor Bethesda MD: National Institute ofAllergy and Infectious Diseases; 1976. 143 pp.
7. Johnson AH. Antiglobulin microcytotoxicity test. In Manual of tissue typing techniques. Bethesda MD: National Institute of Allergy and Infectious Dis-eases; 1979. pp. 80.
8. Iwaki Y, Lau M, Cook DJ, et al. Crossmatching with B and T cells and flow cytometry. Clin Transpl 1986; 277-284.
9. Zoet YM, Eijsink C, Kardol MJ, et al. The single antigen expressing lines (SALs) concept: an excellent tool for screening for HLA-specific antibodies. Hum Immunol 2005; 66:519-525.
10. Arnold ML, Zacher T, Dechant M, et al. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol 2004; 65:1288-1296.
11. van den Berg-Loonen EM, Terasaki P, Kohanof S, Christiaans MH. Long-itudinal testing of seventy-six renal allograft patients for HLA antibodies: Maastricht experience. Clin Transpl 2006; 305-322.
12. Morales-Buenrostro LE,Terasaki PI, Marino-Vazquez LA, et al. Natural' human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation 2008; 86:1111-1115.
13. Claas FH, Doxiadis II. Human leukocyte antigen antibody detection and kidney allocation within Eurotransplant. Hum Immunol 2009; 70:636-639.
14. Opelz G, Claas FH. Which human leukocyte antigen antibodies are really clinically relevant? Hum Immunol 2009; 70:561-562.
15. Aubert V, Venetz JP, Pantaleo G, Pascual M. Are all donor-specific antibodies detected by solid-phase assay before transplantation clinically relevant? Transplantation 2009; 87:1897-1898.
16. Phelan D, Mohanakumar T, Ramachandran S, Jendrisak MD. Living donor renal transplantation in the presence of donor-specific human leukocyte antigen antibody detected by solid-phase assay. Hum Immunol 2009; 70:584-588.
17. Gupta A, Sinnott P. Clinical relevance of pretransplant human leukocyte antigen donor-specific antibodies in renal patients waiting for a transplant: a riskfactor. Hum Immunol 2009; 70:618-622.
18. Vlad G, Ho EK, Vasilescu ER, et al. Relevance ofdifferent antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival. Hum Immunol 2009; 70:589-594.
19. Gebel HM, Moussa O, Eckels DD, Bray RA. Donor-reactive HLAantibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol 2009; 70:610-617.
20. van den Berg-Loonen EM, Billen EV, Voorter CE, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation 2008; 85:1086-1090.
21. Claas FH, Rahmel A, Doxiadis II. Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program. Transplantation 2009; 88:447-452.
22. Claas FH, Doxiadis II. Management of the highly sensitized patient. Curr Opin Immunol 2009; 21:569-572.